Hair and skin
GT20029
An experimental topical androgen-receptor degrader with an early randomized hair-loss trial; some active groups beat placebo, while others did not.
Randomized phase 2 study in 180 men; short-term hair-count findings with mixed placebo comparisons
Practical use
Evidence interpretation and clinical context
- Read the comparator column
- A baseline change and a placebo-adjusted result answer different questions.
- Keep duration visible
- Twelve weeks does not establish years of benefit or safety.
- Distinguish receptor mechanisms
- A degrader and an antagonist need their own efficacy and exposure evidence.
A different way to affect the receptor — primary or official source
Overview
GT20029 uses a PROTAC approach intended to promote breakdown of the androgen receptor. That differs from occupying and blocking the receptor, as an antagonist does. The clinical program concerns androgenetic alopecia and acne, not anabolic muscle treatment.
Risks and limitations
The phase 2 hair-loss trial reported mostly mild adverse events with similar incidence across groups. Twelve weeks and 180 participants cannot rule out uncommon effects, longer-term toxicity or risks outside the studied population.
How to read this
Hair count changing from baseline does not establish a treatment effect unless the change exceeds the corresponding placebo response. The GT20029 results illustrate that distinction across several active groups.
Research explained
Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study.
Who was studied
180 Chinese adult men with androgenetic alopecia randomized equally to six groups in a 12-week, double-blind trial.
What was found
All four active groups increased target-area non-vellus hair count from baseline. Two active groups significantly exceeded their matched placebo groups; one also improved hair width.
What it cannot establish
The trial was short and restricted to men with a defined severity range. The results do not establish durable cosmetic benefit, long-term safety or effectiveness in other forms of hair loss.
Read the original studyA different way to affect the receptor
Kintor describes GT20029 as a topical PROTAC that degrades androgen-receptor protein. That mechanism remains a drug-development strategy, not proof of a clinical advantage over receptor blockers.
Supporting sourceDevelopment status
The peer-reviewed report is a phase 2 investigation. The sources reviewed here do not establish an approved hair-loss indication; trial authorization and marketing authorization are separate decisions.
Supporting sourceClaims versus findings
Incorrect
Every GT20029 group beat placebo.
Only two of the four active groups showed a significant matched-placebo hair-count advantage.
Check the evidenceCommon questions
Does a topical degrader eliminate systemic risk?
The cited short trial cannot establish that. Local delivery and the intended mechanism do not substitute for adequate safety follow-up.
SourceSources
A different way to affect the receptor — primary or official source
Sources checked 2026-10-01.
General education; not a personal treatment plan.